The results of in vitro and in vivo experiments confirmed the important role of AGAP2‐AS1 in glioma development, and its regulation in glioma may be realized by downregulating the expression of NF‐κB and ERK 1/2 in the TGF‐β signaling pathway. Here, NFKB1 is linked to central nervous system cancer.